Both Apc loss and K-Ras activation in ISCs endorse them a clonal advantage over surrounding stem cells in the mouse intestine, while P53 mutations endow a condition-dependent advantage, especially in colitis-associated colon cancer (31, 32). This evidence concerns the gene APC and malignant colon neoplasm.